Edgar R. Wood

5.4k total citations · 2 hit papers
35 papers, 3.7k citations indexed

About

Edgar R. Wood is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Edgar R. Wood has authored 35 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Organic Chemistry and 14 papers in Oncology. Recurrent topics in Edgar R. Wood's work include HER2/EGFR in Cancer Research (12 papers), Synthesis and biological activity (8 papers) and Quinazolinone synthesis and applications (8 papers). Edgar R. Wood is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Synthesis and biological activity (8 papers) and Quinazolinone synthesis and applications (8 papers). Edgar R. Wood collaborates with scholars based in United States, United Kingdom and Netherlands. Edgar R. Wood's co-authors include Karen Lackey, David W. Rusnak, William C. Earnshaw, Krystal J. Alligood, Tona M. Gilmer, Octerloney B. McDonald, Scott H. Dickerson, Lisa M. Shewchuk, Anne T. Truesdale and Byron Ellis and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and The Journal of Cell Biology.

In The Last Decade

Edgar R. Wood

35 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

2004 881 citations Edgar R. Wood, Anne T. Truesdale et al. Cancer Research profile →
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

2001 590 citations David W. Rusnak, Karen Lackey et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edgar R. Wood United States	24	1.8k	1.3k	694	563	485	35	3.7k
Steven A. Middleton United States	30	1.8k 1.0×	1.2k 0.9×	798 1.1×	373 0.7×	308 0.6×	63	3.7k
Allan Wissner United States	26	1.9k 1.1×	1.9k 1.4×	1.5k 2.1×	1.1k 2.0×	446 0.9×	64	4.2k
Alexander J. Bridges United States	27	4.2k 2.3×	2.1k 1.6×	2.0k 2.9×	533 0.9×	428 0.9×	62	7.1k
Steven W. Elmore United States	24	3.2k 1.8×	1.2k 0.9×	716 1.0×	215 0.4×	151 0.3×	37	4.8k
Liguang Lou China	36	1.9k 1.1×	1.5k 1.1×	697 1.0×	613 1.1×	269 0.6×	135	4.0k
Wilbur R. Leopold United States	32	2.9k 1.6×	2.5k 1.9×	1.0k 1.5×	1.1k 2.0×	379 0.8×	65	5.4k
Markus Wartmann Switzerland	39	3.8k 2.1×	2.1k 1.6×	1.1k 1.6×	680 1.2×	193 0.4×	89	6.9k
Taebo Sim South Korea	31	3.5k 2.0×	1.1k 0.8×	951 1.4×	438 0.8×	147 0.3×	122	5.2k
Arianna Donella‐Deana Italy	33	2.2k 1.2×	731 0.5×	269 0.4×	261 0.5×	176 0.4×	91	3.8k
Sylvie M. Guichard United Kingdom	33	2.3k 1.3×	1.6k 1.2×	555 0.8×	319 0.6×	116 0.2×	96	4.0k

Countries citing papers authored by Edgar R. Wood

Since Specialization

Citations

This map shows the geographic impact of Edgar R. Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edgar R. Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edgar R. Wood more than expected).

Fields of papers citing papers by Edgar R. Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edgar R. Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edgar R. Wood. The network helps show where Edgar R. Wood may publish in the future.

Co-authorship network of co-authors of Edgar R. Wood

This figure shows the co-authorship network connecting the top 25 collaborators of Edgar R. Wood. A scholar is included among the top collaborators of Edgar R. Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edgar R. Wood. Edgar R. Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waterson, Alex G., Kimberly G. Petrov, Keith R. Hornberger, et al.. (2009). Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(5). 1332–1336. 33 indexed citations

Lin, Hong, Dennis S. Yamashita, Jin Zeng, et al.. (2009). 2,3,5-Trisubstituted pyridines as selective AKT inhibitors—Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity. Bioorganic & Medicinal Chemistry Letters. 20(2). 673–678. 11 indexed citations

Gilmer, Tona M., Krystal J. Alligood, David W. Rusnak, et al.. (2008). Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib. Cancer Research. 68(2). 571–579. 51 indexed citations

Rheault, Tara, Thomas R. Caferro, Scott H. Dickerson, et al.. (2008). Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(3). 817–820. 72 indexed citations

Hubbard, Robert D., Scott H. Dickerson, Robert Griffin, et al.. (2008). Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 18(21). 5738–5740. 29 indexed citations

Petrov, Kimberly G., Yuemei Zhang, G. Stuart Cockerill, et al.. (2006). Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorganic & Medicinal Chemistry Letters. 16(17). 4686–4691. 144 indexed citations

Lackey, Karen, Octerloney B. McDonald, Edgar R. Wood, et al.. (2006). Discovery and in vitro Evaluation of Potent Kinase Inhibitors: Pyrido[1′,2′:1,5]pyrazolo[3,4‐d]pyrimidines.. ChemInform. 37(4). 1 indexed citations

McDonald, Octerloney B., Karen Lackey, Ronda G. Davis‐Ward, et al.. (2006). Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(20). 5378–5383. 14 indexed citations

Lackey, Karen, Octerloney B. McDonald, Edgar R. Wood, et al.. (2005). Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1′,2′:1,5]pyrazolo[3,4-d]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 15(16). 3778–3781. 28 indexed citations

10.

Wood, Edgar R., Anne T. Truesdale, Octerloney B. McDonald, et al.. (2004). A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib). Cancer Research. 64(18). 6652–6659. 881 indexed citations breakdown →

11.

Wood, Edgar R., Lee F. Kuyper, Kimberly G. Petrov, et al.. (2004). Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorganic & Medicinal Chemistry Letters. 14(4). 953–957. 111 indexed citations

12.

Gaul, Micheal D., Yu Guo, Karen Affleck, et al.. (2003). Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines. Bioorganic & Medicinal Chemistry Letters. 13(4). 637–640. 40 indexed citations

13.

Lackey, Karen, Sue H. Kadwell, Christine R. Hoffman, et al.. (2002). Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains. Journal of Biological Chemistry. 277(2). 1576–1585. 58 indexed citations

14.

Rusnak, David W., Karen Lackey, Karen Affleck, et al.. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.. PubMed. 1(2). 85–94. 590 indexed citations breakdown →

15.

Chamulitrat, Waleé, Sandra J. Jordan, Ronald P. Mason, et al.. (1995). Targets of Nitric Oxide in a Mouse Model of Liver Inflammation by Corynebacterium parvum. Archives of Biochemistry and Biophysics. 316(1). 30–37. 37 indexed citations

16.

Garvey, Edward P., et al.. (1994). Purification and Characterization of the Constitutive Nitric-Oxide Synthase from Human Placenta. Archives of Biochemistry and Biophysics. 311(2). 235–241. 89 indexed citations

17.

Saitoh, Noriko, I. Goldberg, Edgar R. Wood, & William C. Earnshaw. (1994). ScII: an abundant chromosome scaffold protein is a member of a family of putative ATPases with an unusual predicted tertiary structure.. The Journal of Cell Biology. 127(2). 303–318. 215 indexed citations

18.

Wood, Edgar R. & William C. Earnshaw. (1990). Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II.. The Journal of Cell Biology. 111(6). 2839–2850. 157 indexed citations

19.

Wood, Edgar R. & Steven W. Matson. (1989). The molecular cloning of the gene encoding the Escherichia coli 75-kDa helicase and the determination of its nucleotide sequence and gentic map position. Journal of Biological Chemistry. 264(14). 8297–8303. 21 indexed citations

20.

Wood, Edgar R. & Steven W. Matson. (1987). Purification and characterization of a new DNA-dependent ATPase with helicase activity from Escherichia coli.. Journal of Biological Chemistry. 262(31). 15269–15276. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact